• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Checklist for studies of HIV drug resistance prevalence or incidence: rationale and recommended use.HIV 耐药性流行率或发生率研究检查表:原理和推荐用法。
Lancet HIV. 2023 Oct;10(10):e684-e689. doi: 10.1016/S2352-3018(23)00173-X. Epub 2023 Sep 13.
2
Developing a reporting item checklist for studies of HIV drug resistance prevalence or incidence: a mixed methods study.制定一项关于 HIV 药物耐药性流行率或发生率研究的报告条目清单:混合方法研究。
BMJ Open. 2024 Mar 28;14(3):e080014. doi: 10.1136/bmjopen-2023-080014.
3
HIV-1 viraemia and drug resistance amongst female sex workers in Soweto, South Africa: A cross sectional study.南非索韦托女性性工作者中的HIV-1病毒血症与耐药性:一项横断面研究。
PLoS One. 2017 Dec 15;12(12):e0188606. doi: 10.1371/journal.pone.0188606. eCollection 2017.
4
Comparisons of Primary HIV-1 Drug Resistance between Recent and Chronic HIV-1 Infection within a Sub-Regional Cohort of Asian Patients.亚洲患者次区域队列中近期和慢性HIV-1感染的原发性HIV-1耐药性比较
PLoS One. 2013 Jun 27;8(6):e62057. doi: 10.1371/journal.pone.0062057. Print 2013.
5
Prevalence of acquired and transmitted HIV drug resistance in Iran: a systematic review and meta-analysis.伊朗获得性和传播性 HIV 耐药性的流行情况:系统评价和荟萃分析。
BMC Infect Dis. 2024 Jan 2;24(1):29. doi: 10.1186/s12879-023-08916-3.
6
Sociodemographic, Ecological, and Spatiotemporal Factors Associated with Human Immunodeficiency Virus Drug Resistance in Florida: A Retrospective Analysis.与佛罗里达州人类免疫缺陷病毒耐药性相关的社会人口学、生态学和时空因素:一项回顾性分析。
J Infect Dis. 2021 Mar 3;223(5):866-875. doi: 10.1093/infdis/jiaa413.
7
The prevalence of pre-treatment and acquired HIV drug resistance in Vietnam: a nationally representative survey, 2017-2018.越南治疗前和获得性 HIV 耐药性的流行情况:2017-2018 年全国代表性调查。
J Int AIDS Soc. 2022 Feb;25(2):e25857. doi: 10.1002/jia2.25857.
8
HIV-1 drug resistance and resistance testing.HIV-1耐药性与耐药性检测
Infect Genet Evol. 2016 Dec;46:292-307. doi: 10.1016/j.meegid.2016.08.031. Epub 2016 Aug 29.
9
HIV drug resistance (HIVDR) in antiretroviral therapy-naïve patients in Tanzania not eligible for WHO threshold HIVDR survey is dramatically high.在坦桑尼亚,未接受过抗逆转录病毒治疗的患者中,不符合世界卫生组织耐药阈值调查标准的 HIV 耐药(HIVDR)比例非常高。
PLoS One. 2011;6(8):e23091. doi: 10.1371/journal.pone.0023091. Epub 2011 Aug 19.
10
Evaluation of transmitted HIV drug resistance among recently-infected antenatal clinic attendees in four Central African countries.对四个中非国家近期感染的产前门诊就诊者中传播的艾滋病毒耐药性进行评估。
Antivir Ther. 2009;14(3):401-11. doi: 10.1177/135965350901400313.

引用本文的文献

1
Prevalence of Doravirine Resistance Mutations in a Large-Scale HIV-1 Transmitted Drug Resistance Survey in Buenos Aires, Argentina.阿根廷布宜诺斯艾利斯一项大规模HIV-1传播耐药性调查中多韦拉韦耐药突变的流行情况
Viruses. 2025 May 20;17(5):731. doi: 10.3390/v17050731.
2
Phylogenetic Network Analyses Reveal the Influence of Transmission Clustering on the Spread of HIV Drug Resistance in Quebec from 2002 to 2022.系统发育网络分析揭示了传播聚类对 2002 年至 2022 年魁北克 HIV 耐药性传播的影响。
Viruses. 2024 Jul 31;16(8):1230. doi: 10.3390/v16081230.
3
Prevalence and transmission of pretreatment drug resistance in people living with HIV-1 in Shanghai China, 2017-2021.2017-2021 年中国上海 HIV-1 感染者治疗前耐药性的流行和传播。
Virulence. 2024 Dec;15(1):2373105. doi: 10.1080/21505594.2024.2373105. Epub 2024 Jun 27.
4
Emergence of Acquired Dolutegravir Resistance in Treatment-experienced People With HIV in Lesotho.莱索托接受过治疗的HIV感染者中出现获得性多替拉韦耐药性
Clin Infect Dis. 2024 Nov 22;79(5):1208-1222. doi: 10.1093/cid/ciae185.
5
Developing a reporting item checklist for studies of HIV drug resistance prevalence or incidence: a mixed methods study.制定一项关于 HIV 药物耐药性流行率或发生率研究的报告条目清单:混合方法研究。
BMJ Open. 2024 Mar 28;14(3):e080014. doi: 10.1136/bmjopen-2023-080014.

本文引用的文献

1
Genetic Diversity and Low Therapeutic Impact of Variant-Specific Markers in HIV-1 Pol Proteins.HIV-1多聚蛋白中变异特异性标志物的遗传多样性及低治疗影响
Front Microbiol. 2022 Jul 14;13:866705. doi: 10.3389/fmicb.2022.866705. eCollection 2022.
2
Epidemiology of HIV drug resistance in low- and middle-income countries and WHO global strategy to monitor its emergence.中低收入国家的 HIV 耐药流行病学和世卫组织监测其出现的全球战略。
Curr Opin HIV AIDS. 2022 Jul 1;17(4):229-239. doi: 10.1097/COH.0000000000000743.
3
Developing Reporting Guidelines for Studies of HIV Drug Resistance Prevalence: Protocol for a Mixed Methods Study.制定HIV耐药性流行情况研究报告指南:一项混合方法研究方案
JMIR Res Protoc. 2022 May 13;11(5):e35969. doi: 10.2196/35969.
4
Public availability of HIV-1 drug resistance sequence and treatment data: a systematic review.公开获取 HIV-1 耐药性序列和治疗数据:系统评价。
Lancet Microbe. 2022 May;3(5):e392-e398. doi: 10.1016/S2666-5247(21)00250-0. Epub 2022 Jan 19.
5
Guidelines are needed for studies of pre-treatment HIV drug resistance: a methodological study.需要制定治疗前 HIV 耐药性研究指南:一项方法学研究。
BMC Med Res Methodol. 2021 Apr 19;21(1):76. doi: 10.1186/s12874-021-01258-1.
6
Short Communication: Update in Natural Antiretroviral Resistance-Associated Mutations Among HIV Type 2 Variants and Discrepancies Across HIV Type 2 Resistance Interpretation Tools.短篇通讯:HIV 2 型变异体中天然抗逆转录病毒耐药相关突变的最新情况以及 HIV 2 型耐药性解释工具之间的差异。
AIDS Res Hum Retroviruses. 2021 Oct;37(10):793-795. doi: 10.1089/AID.2020.0180. Epub 2021 Mar 17.
7
Prevalence of pretreatment HIV drug resistance in key populations: a systematic review and meta-analysis.重点人群治疗前 HIV 耐药性的流行情况:系统评价和荟萃分析。
J Int AIDS Soc. 2020 Dec;23(12):e25656. doi: 10.1002/jia2.25656.
8
Addressing Ethical Challenges in US-Based HIV Phylogenetic Research.解决美国 HIV 系统进化研究中的伦理挑战
J Infect Dis. 2020 Nov 13;222(12):1997-2006. doi: 10.1093/infdis/jiaa107.
9
Writing the title and abstract for a research paper: Being concise, precise, and meticulous is the key.为研究论文撰写标题和摘要:关键在于简洁、准确和细致入微。
Saudi J Anaesth. 2019 Apr;13(Suppl 1):S12-S17. doi: 10.4103/sja.SJA_685_18.
10
Evolution of HIV-1 transmitted drug resistance in Italy in the 2007-2014 period: A weighted analysis.2007-2014 年意大利 HIV-1 传播耐药性的演变:加权分析。
J Clin Virol. 2018 Sep;106:49-52. doi: 10.1016/j.jcv.2018.07.009. Epub 2018 Jul 26.

HIV 耐药性流行率或发生率研究检查表:原理和推荐用法。

Checklist for studies of HIV drug resistance prevalence or incidence: rationale and recommended use.

机构信息

Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada; Department of Anesthesia, McMaster University, Hamilton, ON, Canada; Department of Pediatrics, McMaster University, Hamilton, ON, Canada; Biostatistics Unit, Father Sean O'Sullivan Research Centre, St Joseph's Healthcare, Hamilton, ON, Canada; Centre for Development of Best Practices in Health, Yaoundé Central Hospital, Yaoundé, Cameroon; Department of Global Health, Stellenbosch University, Cape Town, South Africa.

Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada.

出版信息

Lancet HIV. 2023 Oct;10(10):e684-e689. doi: 10.1016/S2352-3018(23)00173-X. Epub 2023 Sep 13.

DOI:10.1016/S2352-3018(23)00173-X
PMID:37716367
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11060097/
Abstract

HIV drug resistance (HIVDR) is a major challenge to the effectiveness of antiretroviral therapy. Global efforts in addressing HIVDR require clear, transparent, and replicable reporting in HIVDR studies. We describe the rationale and recommended use of a checklist that should be included in reports of HIVDR incidence and prevalence. After preliminary consultations with experts on HIVDR and establishing the need for guidance on HIVDR reporting, we used a sequential, explanatory, mixed methods approach to create the checklist; together with the accompanying articles, the checklist was reviewed by the authors and validated externally. The checklist for studies on HIVDR prevalence or incidence (CEDRIC-HIV) includes 15 recommended items that would enhance transparency and facilitate interpretation, comparability, and replicability of HIVDR studies. CEDRIC-HIV will help authors of HIVDR studies prepare research reports and assist reviewers and editors in assessments of completeness of reporting. The checklist will also facilitate statistical pooling and interpretation of HIVDR data.

摘要

HIV 耐药性(HIVDR)是抗逆转录病毒疗法有效性的主要挑战。全球应对 HIVDR 的努力需要在 HIVDR 研究中进行清晰、透明和可复制的报告。我们描述了一份清单的基本原理和推荐使用方法,该清单应包含在 HIVDR 发生率和流行率的报告中。在与 HIVDR 专家进行初步磋商并确定需要 HIVDR 报告指南后,我们使用了顺序、解释性、混合方法来创建清单;清单和配套文章一起由作者进行了审查,并进行了外部验证。HIVDR 流行率或发生率研究的清单(CEDRIC-HIV)包括 15 项建议项目,这些项目将提高透明度,并有助于解释、比较和复制 HIVDR 研究。CEDRIC-HIV 将帮助 HIVDR 研究的作者准备研究报告,并协助审查员和编辑评估报告的完整性。该清单还将促进 HIVDR 数据的统计汇总和解释。